Ginkgo Bioworks

Making biology easier to engineer.

Founded 2009

Boston, United States 487 employees Total: $2.55B Biopharma, Biotechnology

General Information

Company Name Ginkgo Bioworks

Founded Year 2009

Location

Boston, United States

Employees 487

Industries Biopharma, Biotechnology

Business Model B2B, Platform, SaaS

Revenue Model Usage Based, Service Fee, Project Based

Offices as of Oct 2026

Boston, United States Cambridge, United States Emeryville, United States CH , The Netherlands

Social

BounceWatch is an independent company data service, not affiliated with Ginkgo Bioworks. To contact Ginkgo Bioworks, visit ginkgobioworks.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ginkgo Bioworks compare?

A PDF of Ginkgo Bioworks and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ginkgo Bioworks soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

From the desk

Is Ginkgo Bioworks on your competitive set?

Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.

Book a 7-day Readout

Discover More

United States Market

Market Signals All Companies

Biopharma

Industry Signals All Companies in United States

Ginkgo Bioworks Alternatives

All Signals Trend Reports

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Revenue Metrics Nov 05, 2026

Ginkgo Bioworks' earnings beat estimates by $0.37.

Product Launch Oct 29, 2026

Ginkgo Bioworks launched the #GinkgoReagents Economy kit, offering lower-cost cell-free protein synthesis reactions.

Event Participation Oct 24, 2026

Ginkgo Bioworks representatives participated in a discussion at the Wisconsin Energy Institute regarding biotechnology and national security.

In The News Oct 23, 2026

Featured on Yahoo Finance: What Ginkgo Bioworks Bears Saw Before The Fall

In The News Oct 20, 2026

Featured on Yahoo Finance: Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Invest...

Feature Release Oct 15, 2026

Ginkgo Bioworks detailed its new next-generation enzyme-engineering stack, combining sequence discovery, AI, physics-based modeling, and autonomous lab execution.

+3 more signals in last 30 days

Ginkgo Bioworks a competitor of yours? Have our desk watch it

AI Insight

Bounce Watch AI

4 days ago

Ginkgo Bioworks is actively demonstrating advancements in its core technology and expanding market engagement. The launch of a next-generation enzyme-engineering stack, combined with a significant volume of CFPS experiments on its Nebula platform, highlights robust product development and operational scaling. Despite some recent market volatility in its stock price, analysts are reassessing its valuation positively due to demand for AI in biotechnology, indicating a strong strategic pivot towards AI-driven solutions and external partnerships like the one with NSF X-Labs.

Signal Types

Product Launch Traction Partnership Market Sentiment Technology Innovation

Strategic Labels

AI Integration Platform Scaling Strategic Alliances

Next Move: Expansion

Impact: 8/10

Ideal For: Biotech Growth Investors — Post-IPO

About Ginkgo Bioworks

Ginkgo Bioworks is pioneering advancements in the field of biotechnology by making biology easier to engineer, fulfilling its promise embodied in the slogan, "Making biology easier to engineer." Founded in 2009, this United States-based company operates at the intersection of Biopharma and Biotechnology.

By leveraging autonomous laboratories, Ginkgo Bioworks aims to revolutionize traditional laboratory processes through robotics, enhancing the productivity of scientists. Its innovative solutions, accessible via the "cloud lab" model, provide advanced Datapoints and Solutions contract research services, making lab operations more efficient and streamlined.

The company recently secured a Grant investment on 01 April 2024 from the Bill & Melinda Gates Foundation, highlighting confidence from major investors in its mission and technological acumen.

Business keywords: Biological Engineering, Synthetic Biology, Automation in Laboratories, Cloud Lab Services, Custom Microbes, Molecular Discovery, Probiotic Development, Organism Licensing, Flavor and Sweetener Engineering, Cosmetic Ingredient Design, Crop Treatment Solutions, Pharmaceutical Applications, Carbon Mitigation, Metabolic Engineering, AI in Biotechnology

Services & Products

Building Autonomous Labs

Providing Cloud Lab Services

R&D Experiment Design

Ginkgo Solutions Team

Ginkgo Datapoints Services

Target Customers

Scientists Biotech Researchers Pharmaceutical Companies Biotech Startups R&D Professionals

Funding Rounds & Investors (21)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	Undisclosed	1	Bill & Melinda Gates Foundation	01 Apr 2024
Support Program	$5.21M	1	DARPA	01 Jan 2024
Grant	Undisclosed	1	National Institute of Food and Agriculture	01 Sep 2023
Post-IPO Equity	$15.86M	1	Ark Invest	01 Oct 2021
Spac Private Placement	$1.73B	1	Soaring Eagle Acquisition Corp	01 May 2021
Support Program	$5.89M	1	DARPA	01 Sep 2020
Late VC	$70.00M	3	General Atlantic, Viking Global Investors +1	01 May 2020
Series E	$290.00M	3	General Atlantic, Viking Global Investors +1	01 Sep 2019
Series D	$275.00M	5	Y Combinator, General Atlantic +3	01 Dec 2017
Support Program	$10.45M	1	DARPA	01 Sep 2017

View All 21 Funding Rounds

Latest News

View All

Ginkgo Bioworks earnings beat by $0.37, revenue topped estimates

Investing.com Nov 05, 2026

Ginkgo Bioworks (DNA) Tops Q3 EPS by 37c

StreetInsider Nov 05, 2026

Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo

Business Wire Nov 05, 2026

What Ginkgo Bioworks Bears Saw Before The Fall

Yahoo Finance Oct 23, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know

Yahoo Finance Oct 20, 2026

Ginkgo Bioworks (DNA) Stock Fair Value Edges Higher After Analysts Reassess AI Demand

Yahoo Finance Oct 14, 2026

Ginkgo Bioworks Alternatives & Competitors

View All Alternatives

Ginkgo Bioworks vs

Absci United States

Unlocking differentiated biology with generative AI

IPO

158 employees

AI, Biopharma

Compare Ginkgo Bioworks vs Absci

Ginkgo Bioworks vs

BDD United Kingdom

Redefining Early Stage Development

Venture round

54 employees

Biopharma, Biotechnology

Ginkgo Bioworks vs

Discover Echo Inc. United States

Experience Precision in Biological Research with Advanced Automated Microscopy for Accurate Imaging...

Series A

68 employees

Biopharma, Biotechnology

Compare Ginkgo Bioworks vs Discover Echo Inc.

View all alternatives

FAQ About Ginkgo Bioworks

Making biology easier to engineer.

Ginkgo Bioworks was founded in 2009.

Ginkgo Bioworks is headquartered in Boston, United States. As of Oct 2026, it also has offices in Cambridge, United States, Emeryville, United States and CH , The Netherlands.

Ginkgo Bioworks operates in Biopharma and Biotechnology. Its work centres on Biological Engineering, Synthetic Biology, Automation in Laboratories and Cloud Lab Services. Its customers include Scientists, Biotech Researchers and Pharmaceutical Companies.

Ginkgo Bioworks has a B2B, Platform and SaaS business model. Its revenue comes from Usage Based, Service Fee and Project Based.

Ginkgo Bioworks has approximately 487 employees.

Ginkgo Bioworks has completed 21 funding rounds, raising a total of $2.55B.

Ginkgo Bioworks offers: Building Autonomous Labs, Providing Cloud Lab Services, R&D Experiment Design, Ginkgo Solutions Team, Ginkgo Datapoints Services.

Top alternatives and competitors to Ginkgo Bioworks include Absci, BDD, Discover Echo Inc., Apostle Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Ginkgo Bioworks and Absci are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ginkgo Bioworks, https://bouncewatch.com/company/gingko-bioworks, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Ginkgo Bioworks

General Information

Discover More

What changed at Ginkgo Bioworks recently?

AI Insight

About Ginkgo Bioworks

Services & Products

Target Customers

Funding Rounds & Investors (21)

Latest News

Ginkgo Bioworks Alternatives & Competitors

FAQ About Ginkgo Bioworks